Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
AMLX · against 290 other Healthcare companies of similar size
Ranked #222 of 291 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score70 peers with a valuation score of 0–9, including AMLX · Click a bar to see the companies
Mainly because of its EBITDA yield and earnings yield, which are weaker than most Healthcare peers.
| Metric | AMLX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 287 reported | -4.8% | 2.5% | 18% | 30% | |
| EBITDA yieldHigher is better · 286 reported | -5.3% | 4.8% | 14% | 50% | |
| Free cash flow yieldHigher is better · 151 reported | -3.5% | 0.8% | 31% | 20% | |
| Book yieldHigher is better · 285 reported | 7.4% | 28.4% | 12% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 5 | 21.1B HKD (≈$2.7B) | 98 | 67 | |
| 221 | 13.9B CNY (≈$1.9B) | 29 | 29 | |
| 222 | 3.9B USD | 8 | 47 | |
| 222 | 4.1B USD | 8 | 39 | |
| 222 | 1.9B USD | 8 | 49 | |
| 222 | 3.7B USD | 8 | 31 | |
| 222 | 2.9B USD | 8 | 44 | |
| 222 | 7.3B USD | 8 | 32 | |
| 222 | 2.2B USD | 8 | 32 | |
| 222 | 2.7B USD | 8 | 50 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score